View in EDS HTML Full Text PDF Full Text

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.

Saved in:
Bibliographic Details
Title: Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
Authors: Kim H; Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, 19104, USA., Xu H; Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, 19104, USA., George E; Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, 19104, USA., Hallberg D; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA., Kumar S; Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, 19104, USA., Jagannathan V; Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA., Medvedev S; Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, 19104, USA., Kinose Y; Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, 19104, USA., Devins K; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA., Verma P; Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA., Ly K; Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, 19104, USA., Wang Y; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA., Greenberg RA; Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA., Schwartz L; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA., Johnson N; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA., Scharpf RB; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA., Mills GB; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University School of Medicine, Portland, OR, 97239, USA., Zhang R; Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA, 19104, USA., Velculescu VE; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA., Brown EJ; Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA., Simpkins F; Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, 19104, USA. fiona.simpkins@pennmedicine.upenn.edu.
Source: Nature communications [Nat Commun] 2020 Jul 24; Vol. 11 (1), pp. 3726. Date of Electronic Publication: 2020 Jul 24.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2041-1723
DOI:10.1038/s41467-020-17127-2